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Molecular imaging by micro-CT: specific
E-selectin imaging
Abstract The primary goal of this
study was to design a fluorescent
E-selectin-targeted iodine-containing
liposome for specific E-selectin
imaging with the use of micro-CT.
The secondary goal was to correlate
the results of micro-CT imaging with
other imaging techniques with cellular
resolution, i.e., confocal and intravital
microscopy. E-selectin-targeted lipo-
somes were tested on endothelial cells
in culture and in vivo in HT-29 tumor-
bearing mice (n=12). The liposomes
contained iodine (as micro-CT con-
trast medium) and fluorophore (as
optical contrast medium) for confocal
and intravital microscopy. Optical
imaging methods were used to con-
firm at the cellular level, the observa-
tions made with micro-CT. An
ischemia-reperfusion model was used
to trigger neovessel formation for
intravital imaging. The E-selectin-
targeted liposomes were avidly taken
up by activated endothelial cells,
whereas nontargeted liposomes were
not. Direct binding of the E-selectin-
targeted liposomes was proved by
intravital microscopy, where bright
spots clearly appeared on the activated
vessels. Micro-CT imaging also
demonstrated accumulation of the
targeted lipsomes into subcutaneous
tumor by an increase of 32±8 HU.
Hence, internalization by activated
endothelial cells was rapid and
mediated by E-selectin. We conclude
that micro-CT associated with specific
molecular contrast agent is able to
detect specific molecular markers on
activated vessel walls in vivo.
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Introduction
Molecular imaging, i.e., the measurement and/or imaging
of biological processes in living organisms at the molecular
and cellular level, is now part of the preclinical world and
even part of the clinical world for imaging modalities such
as positron-emission tomography [1]. Previous reports
have already proved that molecular imaging is feasible by
nuclear medicine [2], magnetic resonance [3, 4] and optical
[5] imaging. Micro-computed tomography (micro-CT) has
not been used widely in this field. The addition of this
imaging technique into the molecular world will expand
the molecular “toolbox” and hence the possibilities of
research. We present here proof that micro-CT, associated
with specific contrast media, is able to detect the presence
of specific molecular markers on activated endothelial
cells. More specifically, we chose to target E-selectin
expression on activated endothelial cells.
E-selectin (also known as CD62E) is an inducible cell-
adhesion molecule belonging to the C-type lectin family
[6]; it is expressed on the surface of endothelial cells in
response to inflammatory processes [7] or on proliferating
endothelial cells [8], but not on quiescent cells. Hence, the
differential expression of E-selectin between activated and
nonactivated cells makes E-selectin an optimal candidate
for molecular imaging. Targeting E-selectin will allow
specific imaging of activated vessels. Peptides that
specifically bind to E-selectin [7, 9] were selected from a
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recombinant peptide library and showed affinity in the low
nanomolar range [7].
Previous studies have demonstrated that iodinated
liposomes are useful contrast media for micro-CT [10,
11]. As liposomes are composed of uni- or bilamellar
membranes entrapping contrast media (iodine in case of
micro-CT), we postulated that post-insertion of specific
targeting moieties into the membrane of liposomes should
be possible, as previous work on targeted liposomes has
already been published [12, 13]. Hence, we have
synthesized iodinated liposomes targeting the expression
of E-selectin on activated endothelial cells and applied this
contrast media to detect the expression of E-selectin on
activated endothelial cells by micro-CT imaging.
Materials and methods
Synthesis of the E-selectin-targeted liposomes
and iodinated unilamellar liposomes
E-selectin-binding peptide (ESBP) with the following
sequence (FITC)BCDSDSDITW-DQLWDLMK (B stands
for beta-alanine, FITC for fluorescein) was purchased from
Tufts University (Tufts University, Boston, MA, USA).
To synthesize E-selectin-targeted liposomes (Fig. 1),
100 μl of 1 mM 1,2-distearoyl-sn-glycerol-3-phosphoetha-
nolamine-N-[amino(polyethylene glycol)-2000] (DSPE-
PEG-2000, Avanti Polar Lipids) was activated with 100 μl
of 150 mM succinimidyl iodoacetic acid (SIA; Molecular
Biosciences, CO, USA) in dimethylsulfoxide (DMSO), and
the mixture was allowed to stand at room temperature for
30 min. The ESBP was then added to 1.25 mg peptide in
100 μl DMSO, and the mixture was allowed to stand
overnight at room temperature. The resulting ESBP-DSPE-
PEG-2000 was purified twice through exclusion chroma-
tography (PD10 column, GE Healthcare, Otelfingen,
Switzerland) in phosphate buffer saline (PBS). Then the
ESBP-DSPE-PEG-2000 was post-inserted in 4 ml iodinated
liposomes by gentle stirring overnight to generate ESBP-
liposomes. Fluorescent DSPE-PEG-2000 was obtained by
covalently binding NHS ester of indocyanin 3.5 (Cy3.5)
according to the manufacturers’ instructions (Amersham
Biosciences, Piscataway, NJ, USA) and was purified twice
by exclusion chromatography and post-inserted in 4 ml
iodinated liposomes. The fluorescence of the FITC on the
ESBP allowed quantification of the peptide/DSPE-PEG-
2000 liposome ratio. The average number of peptides
post-inserted into liposomes was determined spectrophoto-
metrically from fluorescein absorbance at 493 nm [14]
using a concentration of 1.25×1013 liposomes/ml, and the
average number of Cy3.5 post-inserted into liposomes was
determined from its absorption at 580 nm. The size of the
various liposomes was determined by laser light scattering
(Zetasizer, Malvern Instruments, Malvern, PA, USA).
Iodinated unilamellar liposomes (BR22, 400±50 nm
diameter as determined by laser light scattering), prepared
by a film/extrusionmethod as described previously [15], were
provided by Bracco Research (Bracco Research, Plan-les-
Ouates, Geneva, Switzerland). To avoid leakage of the
iodine due to equilibration of the internal and external phases,
iodine [Iomeprolum; (N,N-bis (2,3-dihydroxypropyl)-5-
[(hydroxy-acetyl)-methylamino]–2,4,6-tri-iodo-1,3 benzene-
dicardoxamide)], Bracco Switzerland, Switzerland) was also
present in the external phase. These unilamellar liposomes
entrapped 70 mg iodine/ml equilibrated with 287 mg iodine/
ml in the external phase. Nontargeted iodinated liposomes
were used as control.
In vitro analysis
Confocal microscopy
To study the specificity of ESBP-liposomes, EC219 cells
were grown on histological slides.
Fig. 1 Synthesis of ESBP-lipo-
somes. DSPE-PEG-2000 was
first activated with succinimidyl
iodoacetic acid (SIA) (1). The
terminal NH2 group of DSPE-
PEG-2000 was reacted with the
NHS ester of the SIA. Then,
the lateral sulfhydryl group of
the cysteine (second amino acid
of the ESBP) was reacted with
the iodoacetyl group of the
activated DSPE-PEG-2000 (2)
to form a covalent bond between
the ESBP and the DSPE-PEG-
2000. The resulting ESBP-
DSPE-PEG-2000 was then
inserted into preformed
iodinated liposomes (3)
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Activation of the cells was undertaken through stimu-
lation with 200 U/ml mouse TNF-a and 50 U/ml rat IFN-g
(Roche Diagnostic, Mannheim, Germany) over a 24-h
period. Nonactivated cells served as control.
ESBP-liposomes (200 μl of the stock solution, corre-
sponding to 14 mg iodine) were added to nonactivated and
cytokine-activated cells for 4 h, then rinsed twice with PBS
and fixed for 5 min in buffered 4% formaldehyde. Cells
were then rinsed twice in PBS and mounted in immuno-
mount (Thermo Shandon, Pittsburg, PA, USA). Imaging
was performed on a Leica SP5 confocal microscope (Leica
Microsystems, Wetzlar, Germany) using filters of 580
(excitation)/610 (emission). Activation of the cells was
proved by an increase in NO synthesis, as previously
published [19].
In vivo analysis
Two types of models of neovessel formation were used in
this study. The first one consisted of an ischemia-
reperfusion model, which was used for intravital micros-
copy (see below). The second one consisted of tumor
neovessel formation, which was used for micro-CT
imaging.
Animal preparation for intravital microscopy
All the experiments using mice were approved by the local
ethics committee and followed the Swiss guidelines for
animal experiments.
The dorsal skinfold chamber preparation in five awake
C57BL/6 mice (Janvier, le Genest-St-Isle, France) was
used for intravital microscopy. The experimental prepara-
tion used in this study was very similar to that described
previously [16]. Briefly, C57BL/6 mice were fed standard
rodent diet and allowed water ad libitum; they were
anesthetized by injection of ketamine 100 mg/kg IP
(Ketavet, Pharmacia, Erlangen, Germany) and xylazine
20 mg/kg IP (Rompun, Bayer, Leverkusen, Germany).
Two titanium frames were implanted so as to sandwich the
extended double layer of the skin. One layer of the skin was
completely removed in an 18-mm-diameter circular area,
and the remaining layer, consisting of epidermis, subcuta-
neous tissue, and a thin striated skin muscle, was covered
with a coverslip incorporated in one of the frames. The
dorsal skinfold chambers were well tolerated by the
animals, i.e., they showed no signs of discomfort and no
adverse effects on feeding and sleeping habits.
Ischemia-reperfusion
An ischemia model was used to trigger neovessel forma-
tion. The experimental protocol was performed as described
previously [17]. A 2-h period of ischemia was induced by
application of gentle pressure on the muscle against a
coverslip with a silicone pad and an adjustable screw that
was just sufficient to empty the blood vessels [17].
Intravital fluorescence microscopy
Between the implantation of the observation chamber and
the microscopic investigation, a recovery period of 72–96 h
was allowed to eliminate the effects of anesthesia and
surgical trauma on the microvasculature. Epi-illumination
(100-W xenon lamp attached to an Axiotech intravital
microscope, Zeiss, Jena, Germany) and a 20× water
immersion objective (total magnification 560×; Zeiss)
were used to select 10 regions of interest per chamber, each
containing ≥1 venule of various diameters. Awake animals
were then imaged in bright field and fluorescence imaging
before and after intravenous (iv) injection of 400 μl of
either ESPB-liposomes or liposomes. Postinjection images
were taken immediately after injection as well as after 1
and 2 h. The microscopic images were recorded with a
high-resolution black-and-white camera (Kappa, Gleichen,
Germany) on DVD video.
All animals were euthanized after the last imaging
session with a single injection of KCl (200 mEq/kg).
Animal model for micro-CT
Cell culture
The human colon adenocarcinoma cell line HT-29 was
obtained from LGC Promochem (LGC Promochem,
France). Cells were cultured in McCoy’s 5a medium
modified with 1.5 mM L-glutamine and adjusted to contain
2.2 g/L sodium bicarbonate and 10% heat-inactivated fetal
bovine serum (all from GIBCO, Invitrogen, Switzerland),
and grown at 37°C in a humidified 5% CO2 atmosphere.
In vivo studies
Athymic female nude mice (Janvier, le Genest-St-Isle,
France) weighing 20–25 g were used in this study. Gas
anesthesia (isoflurane 1–2%) was used during all injection
of contrast media, as well as during all surgical procedures
and micro-CT imaging sessions. Both ESBP-liposomes
and nontargeted iodinated liposomes were injected through
the tail vein of the animals.
Tumor-bearing animals
After anesthesia (isoflurane 1–2%) and local disinfection,
tumor cells were injected subcutaneously (1 million cells in
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50 μl PBS) into the left and right paralumbar regions.
Tumor cells were allowed to grow for 5–6 days and then
imaged with a micro-CT after injection of 400 μl ESBP-
liposomes (n=6) or 400 μl liposomes (n=6), corresponding
to 28 mg of iodine. All animals were euthanized after
the last imaging session with a single injection of KCl
(200 mEq/kg).
Micro-CT acquisition
All images were acquired on a Skyscan-1076 micro-CT
(Skyscan, Aartselaar, Belgium). All in vivo micro-CT
examinations were acquired at 35-μm resolution using
the following parameters: 65 kV anode voltage, 180 μA,
1.4° rotation step, 316 ms exposure time per view. A
0.5-mm aluminum filter was installed in the beam path
to cut off the softest x-rays in order to increase the
accuracy of the beam-hardening correction (BHC). These
settings allowed scanning an entire mouse at 35-μm
resolution in 30 min [each mouse received an estimated
dose of 0.7 Gy during the image acquisition (data from
the manufacturer)]. All animals were imaged before and
immediately after injection of the probes and after 1, 2,
4, 6, 8, and 24 h.
Image reconstruction and analysis
Cross-sectional images were reconstructed using a classical
Feldkamp cone-beam algorithm [18]. The corrected image
data were calibrated into the conventional linear scale
of CT number, known as Hounsfield units (HU), defined
so that water and air have values of 0 and -1,000 HU,
respectively.
Regions of interests (ROIs) were manually drawn to
assess attenuation coefficients in HU in the blood-filled
chamber of the left and right ventricles, as well as in the
tumor. A monoexponential fit of the signal measured in the
blood-filled chambers of the heart gave the blood half-life
of the different contrast media. The enhancement of the
tumor over time was also assessed.
Statistical analysis was performed with Prism 4 (Graph-
Pad Prism, version 4a, 2003, GraphPad Software, San
Diego, CA, USA). Data are reported as mean ± standard
error (SE). Significance was determined using Mann-
Whitney test; P values < 0.05 were considered significant.
To compare different groups, ANOVA analysis was
used. When a significant P value was found (P<0.05), a
Bonferroni’s post-test correction was performed.
Histology
All tumors were excised, snap frozen, and cut into 7-µm
sections using a CM3050 cryostat (Leica Microsystems,
Germany). Sections were stained with hematoxylin-
eosin (HE). Immunohistochemistry was conducted on
acetone-fixed cryosections, which were blocked with
PBS containing 0.5% donkey serum and 2% BSA, and
incubated for 1 h with the ESBP peptide at 1 µg/ml and rat
anti-mouse CD31 diluted 1:200 (Molecular Probes, Invi-
trogen, Switzerland). A secondary antibody (donkey anti-
rat; TexasRed, Jackson Immunoresearch Europe) was
applied at 1:500 for 1 h. Nuclear staining was obtained
with a mounting medium containing DAPI (Vectashield
hard set with DAPI, Vector Laboratories, Burlingame, CA,
USA).
Results
ESBP-liposomes characterization
The average size of the liposomes used in this study was
400 nm. The average number of peptides inserted into
preformed liposomes, determined spectrophotometrically,
was 1,492 ESBP per liposomes. The average number of
Cy3.5 molecules per liposome was 120.
Activation of endothelial cells
Activation of endothelial cells with TNF-α and IFN-γ was
verified through their production of nitric oxide (NO), as
previously published [19]. Activated endothelial cells
produced 5.3 μM NO per 72 h, whereas control cells
(nonactivated) produced 0.05 μM NO per 72 h.
Confocal imaging
The specificity of the interaction of ESBP-liposomes with
E-selectin in vitro was examined by confocal microscopy
on cytokine-activated and nonactivated cells. Nonactivated
cells showed almost no binding of the ESBP-liposomes,
whereas activated cells showed accumulation of the ESBP-
liposomesvisible throughout the cytoplasm as punctuated
centers of fluorescence. Stimulated cells without ESBP-
liposomes (used as control) showed no fluorescence (see
Fig. 2).
Intravital microscopy
All the implanted dorsal chambers were of good quality
and permitted image acquisition. The acquisition of images
before administration of the ESBP-liposomes or liposomes
showed no fluorescence inside the vessels (see Fig. 3a and
d). Immediately after iv administration of the contrast
media, a clear fluorescent signal was present in the plasma
(see Fig. 3b and e), but no accumulation was detected in the
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vessel walls. Two hours after injection of the ESBP-
liposomes, bright spots accumulated in the walls of veins,
whereas there was no bright signal on the arterioles (see
Fig. 3c). The control probe (liposomes without targeting)
showed no accumulation on the vessel wall (see Fig. 3f).
Tumor implantation and micro-CT imaging
All mice developed small (3–5 mm) tumors after 5–6 days.
All micro-CT acquisitions were of good quality and
allowed for blood half-life calculations of the probes (see
Fig. 4a and c) as well as for tumor imaging (see Fig. 4b and
d). Blood half-lives of the ESBP-liposomes and liposomes
were 121 (± 11) and 71 (± 18) min, respectively. Small
subcutaneous tumors were easily visible and showed
greater enhancement after injection of ESBP-liposomes
than after liposomes (see Fig. 4d). Nontargeted liposomes
showed a simple disappearance from the blood, corre-
sponding to the blood half-lives of the probes. In contrast,
ESBP-liposomes showed first a binding on the tumor
vessels followed by clearing. Enhancement after injection
of the probes was different between the two probes at 120,
240, and 360 min with ESBP-liposomes being trapped in
the tumor’s vessels for a longer time. The residency time of
the ESBP-liposomes inside the tumor was 314±2 min,
whereas residency time for nontargeted liposomes was
only 90±1 min (P<0.001).
Fig. 3 Intravital microscopy. Low background signal was observed
on intravital microscopy (a and d). The plasma became highly
fluorescent after intravenous injection of either ESBP-liposomes (b)
or nontargeted liposomes (e). Two hours after the iv injection, bright
spots appeared when ESBP-liposomes were injected (c), whereas no
fluorescent signal was seen when nontargeted liposomes were
injected (f). Note that the majority of bright spots appearing after
injection of ESBP-liposomes are located on the postcapillary veins
Fig. 2 Confocal microscopy.
Phase contrast images (top row)
as well as fluorescence
imaging (bottom row) are
shown. Cytokine-activated
endothelial cells incubated with
ESBP-liposomes showed a
clear cytoplasmatic signal (a),
whereas activated endothelial
cells without ESBP-liposomes
showed none (b). Nonactivated
endothelial cells incubated with
ESBP-liposomes showed almost
no intracellular signal (c)
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Histology
Hematoxylin and eosin staining confirmed the presence of
small tumors in all animals (see Fig. 5). Immunohisto-
chemistry showed a good colocalization between ESBP
and CD31.
Discussion
Molecular imaging has already been demonstrated with
nuclear medicine, MRI, and optical imaging. Micro-CT has
never been used to directly interrogate molecular markers
on the surface of cells. This study demonstrates that the use
of micro-CT, combined with targeted liposomes directed
against E-selectin expression on activated endothelial cells,
enables direct imaging of this receptor.
E-selectin is expressed on activated endothelial cells and
plays important roles in leukocyte rolling during inflam-
matory processes or angiogenesis [20, 21]. Moreover, as
E-selectin is expressed on the surface of activated endo-
thelial cells, an intravenous injection allows the E-selectin-
targeted contrast medium to be in direct contact with its
molecular target without the need to extravasate. The
liposomes used in this study have a diameter of 400 nm.
This relatively big size makes the liposomes an intravas-
Fig. 5 Correlative histology. Hematoxilin and eosin staining (a) of
the subcutaneous tumor. Immunohistochemistry against E-selectin
(b), CD31 (c), and DAPI staining of the nuclei (d), as well as merge
(e) are presented. The histology confirmed the presence of E-selectin
on the endothelial cells (colocalization with CD31)
Fig. 4 In vivo micro-CT imaging. Determination of the blood half-
lives of the compounds. Heart cavities were used to generate signal
(in Hounsfield units) versus time (a). A monoexponential fit (b)
allowed the blood half-lives of the ESBP-liposomes (121 min) and
nontargeted liposomes (71 min) to be calculated. This difference in
blood half-lives was not statistically significant (P=0.24). Acquisi-
tion of the micro-CT images in the tumor region (c) showed a clear
enhancement of the subcutaneous tumor (arrow). The evolution of
the density of the tumor versus time is presented (d) for the ESBP-
liposomes as well as for the nontargeted liposomes. Differences
between the two contrast media reached statistical difference at 120,
240, and 360 min. ESBP-liposomes accumulated in the tumor,
whereas nontargeted liposomes disappeared from the blood
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cular contrast medium, with no chance for the compound to
pass through the endothelial barrier [22]. At the same time,
the size also increases the blood half-life of the compound
[10], which gives more time for the targeted compound to
interact with its molecular target. Hence, liposomes of such
size are ideal candidates for molecular imaging of intravas-
cular targets. The use of smaller liposomes would be
necessary to reach extravascular targets. The general prin-
ciple of extravasation and uptake of microparticles into cells
through endocytic routes is nowwell accepted. Discussion in
many review articles suggests that, for this process to occur
efficiently, particle sizes need to be less than 100 nm [22].
Synthesis of small liposomes (as small as 50 nm) has already
been published [23, 24]. Such small liposomes should be
able to extravasate from neovessels and reach extravascular
targets. Future studies are needed to evaluate the utility of
such a compound for molecular imaging.
The targeting moiety used in this study (ESBP) is known
to be specific for E-selectin [5], with a high affinity
constant, on the order of a few nanomoles [7]. Our in vitro
experiments (confocal microscopy) indicate that quiescent
endothelial cells do not bind to the targeted liposomes,
whereas activated cells do (see Fig. 2).
Our in vivo experiments (intravital microscopy and
micro-CT imaging) indicate that targeted liposomes
accumulate in the veins where the endothelium has been
activated, whereas nontargeted liposomes do not (see
Figs. 3 and 4). Intravital microscopy, which was performed
on awake mice, clearly shows bright spots on the
postcapillary veins, but not on the arterial wall. This
finding is consistent with previous results showing that E-
selectin binding is more potent at low flow [25].
In vivo accumulation of the targeted ESBP-liposomes
into subcutaneous tumorswas proved bymicro-CT imaging.
Micro-CT offers extremely high-resolution images with
good contrast among air, bone, fat, and soft tissue, but
suffers from inherently poor contrast among soft tissues.
Hence, injection of exogenous contrast medium is manda-
tory to differentiate soft tissue by micro-CT [10, 11]. One of
the most used exogenous contrast media in the clinics is
iodine, which absorbs x-rays efficiently. The presence of
iodine in a voxel of the image induces x-ray absorption and
an increase in density. Hence, accumulation of ESBP-
liposomes into the tumor induces an increase in density. The
kinetics of accumulation of the ESBP-liposomes is also
different from that of the nontargeted one. ESBP-liposomes
first show an accumulation over 60 min, corresponding to
progressive binding, then a slow decrease, whereas
nontargeted liposomes show a monoexponential decay,
corresponding to the blood half-lives of the compound.
Competition or blocking experiments have not been
performed because of the difficulties in displacing a
multivalent compound [12]. The affinity of multivalent
compounds is higher than their monovalent counterpart.
Hence their displacement is virtually impossible by
classical competition or blocking experiments.
Study limitation
Biodistribution of the E-selectin-targeted liposomes was not
assessed in this study because it was outside the scope of the
primary goal. Nevertheless, biodistribution should be
studied in the future, if one wants to use this compound.
Toxicity of the compoundswas also not tested, but we do not
expect any toxicity of the compounds because the iodinated
liposomes have already been in phase II clinical study and
the adjunction of a small peptide should not be toxic.
Despite the use of two animal models (ischemia-
reperfusion for intravital microscopy and implanted tumors
for micro-CT imaging), we believe this paper clearly
demonstrated (1) the binding of the targeted compounds at
a cellular resolution (by confocal microscopy), (2) the
binding of the targeted compounds to activated vessels in
vivo (by intravital microscopy) and (3) the binding of the
targeted compounds to activated vessels in tumor (by
micro-CT).
Conclusions
This study demonstrates that micro-CT, associated with
targeted iodinated liposomes can identify a molecular
target on the endothelium, enabling the realization of
molecular imaging.
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